Article · 13 Feb 2026
Conference abstractPublished 8 Sep 2014
Regulatory affairs in herbal products - Indian perspective
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Out of ca 17500 plant species in India, approx. 3000 species are used in Indian system of medicine including around 30 in modern medicine. About 90% of these medicinal herbs are collected from the wild. Safety and quality of herbal medicines have become increasingly important as no standard process is followed for the collection and the collectors are not sufficiently trained. Market potential is curtailed by lack of standardization of many herbal medicines. Quality lacks in raw material production, garbling, packing, labeling etc. There is no validation of efficacy and safety. Presence of extraneous matter (adulterants), microbial contamination and production of toxic materials are also the matter of concern. Genetic variants, geographical and nutritional factors and seasonal changes are some of the factors influencing the physico-chemical profile of medicinal plants. Authentication of medicinal herbs is a vital issue. Good agricultural and collection production address some of the issues. In herbal products, quality is wholesome which should have some statutory requirements, market expectation and technical experience. Some newly emerging techniques viz., Herbopoint capillary electrophoresis (HPLC finger print, electrophoresis) and DNA analysis (RAPD, AFLP, RFLP and ISSR) are successfully employed for characterization of semi processed and processed herbal drug materials. Good agricultural practices (GCP), good manufacturing practices guidelines have now become an intrinsic part of quality assurance system. Realistic quality control in medicinal and aromatic plants involves GAP, GCP and GMP and considers the entire processes from raw material to final products.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “D D Patra”
